Investing
Bristol-Myers Squibb·Cash Flow Statement·8 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Proceeds from Sale of Retained Ownership Interests | $55M | $0 | $205M | $12M | $0 | $49M | $16M | $391M |
| Proceeds from disposal of certain strategic investments | $55M | $0 | $205M | $12M | $0 | $49M | $16M | $391M |
| Proceeds from Sale of Seagen Inc. Common Stock | $55M | $0 | $205M | $12M | $0 | $49M | $16M | $391M |
| Proceeds From Sale And Maturity Of Available For Sale Securities | $75M | $238M | $62M | $220M | $524M | $829M | $402M | $359M |
| Capital expenditures | $262M | $324M | $378M | $260M | $361M | $320M | $370M | $347M |
| Divestiture and other proceeds | $274.8M | $274.8M | $274.8M | $243M | — | — | — | $312M |
| Net cash from investing activities | -$1.3B | -$219M | -$196M | -$499M | -$473M | -$1.7B | -$1.5B | -$131M |
| Acquisitions, net of cash acquired | $1.4B | $348M | $47M | $78M | $285M | $1.9B | $1.7B | $65M |